NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free MYNZ Stock Alerts $0.86 -0.04 (-4.66%) (As of 05:44 PM ET) Add Compare Share Share Today's Range$0.81▼$1.0850-Day Range$0.87▼$1.1252-Week Range$0.81▼$6.00Volume1.08 million shsAverage Volume94,688 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Mainz Biomed alerts: Email Address Mainz Biomed MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside600.3% Upside$6.00 Price TargetShort InterestHealthy2.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 stars 3.3 Analyst's Opinion Consensus RatingMainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMainz Biomed has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.30% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently decreased by 1.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYNZ. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Mainz Biomed this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for MYNZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Mainz Biomed Stock (NASDAQ:MYNZ)Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.Read More MYNZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYNZ Stock News HeadlinesApril 25, 2024 | globenewswire.comMainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer DiagnosticApril 17, 2024 | msn.comMainz Biomed N.V. (MYNZ) Price Target Decreased by 9.09% to 5.10April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 10, 2024 | finance.yahoo.comThe Pharmaceutical Industry Finds Itself At A Historical CrossroadsApril 9, 2024 | investorplace.comMYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023April 9, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Reports Full Year 2023 Financial ResultsApril 9, 2024 | globenewswire.comMainz Biomed Reports Full Year 2023 Financial ResultsApril 5, 2024 | seekingalpha.comMYNZ Mainz Biomed N.V.April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 2, 2024 | benzinga.comPharma's Post-Pandemic Story To Unlock A Cancer-Free EraMarch 19, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentMarch 19, 2024 | globenewswire.comMainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentMarch 18, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsMarch 18, 2024 | globenewswire.comMainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsMarch 12, 2024 | finanznachrichten.deMainz BioMed NV: Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 12, 2024 | globenewswire.comMainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 5, 2024 | globenewswire.comMainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer DiagnosticFebruary 27, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical CommunityFebruary 27, 2024 | globenewswire.comMainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical CommunityFebruary 22, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®February 22, 2024 | finanznachrichten.deMainz BioMed NV: Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlertFebruary 22, 2024 | finance.yahoo.comMainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®February 22, 2024 | globenewswire.comMainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®February 21, 2024 | finanznachrichten.deEQS-News: Mainz BioMed N.V.: Mainz Biomed geht strategische Partnerschaft mit TomaLab zur Ausweitung der Verfügbarkeit von ColoAlert® in Italien einFebruary 21, 2024 | finanznachrichten.deMainz BioMed NV: Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert in ItalyFebruary 21, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in ItalyFebruary 21, 2024 | finance.yahoo.comMainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in ItalySee More Headlines Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/09/2024Today4/25/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MYNZ CUSIPN/A CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+622.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,300,000.00 Net Margins-2,934.82% Pretax Margin-2,938.10% Return on Equity-488.05% Return on Assets-145.77% Debt Debt-to-Equity Ratio0.36 Current Ratio0.97 Quick Ratio0.91 Sales & Book Value Annual Sales$900,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book3.07Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.24 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Guido Baechler (Age 59)CEO & Executive Director Mr. William J. Caragol (Age 57)Chief Financial Officer Dr. Christopher Von Torne P.M.P. (Age 52)Ph.D., Chief Operating Officer Dr. Frank Krieg-Schneider (Age 62)Chief Technology Officer Dr. Moritz Eidens Ph.D. (Age 40)Chief Science Officer & Executive Director Stefan ErlachHead of Human ResourcesMr. Philipp Freese (Age 41)Chief Business Officer Mr. Darin S. Leigh (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors MYNZ Stock Analysis - Frequently Asked Questions Should I buy or sell Mainz Biomed stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mainz Biomed in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MYNZ shares. View MYNZ analyst ratings or view top-rated stocks. What is Mainz Biomed's stock price target for 2024? 2 brokerages have issued 12 month price objectives for Mainz Biomed's stock. Their MYNZ share price targets range from $3.00 to $9.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 600.3% from the stock's current price. View analysts price targets for MYNZ or view top-rated stocks among Wall Street analysts. How have MYNZ shares performed in 2024? Mainz Biomed's stock was trading at $1.16 at the start of the year. Since then, MYNZ shares have decreased by 26.1% and is now trading at $0.8568. View the best growth stocks for 2024 here. When is Mainz Biomed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our MYNZ earnings forecast. How were Mainz Biomed's earnings last quarter? Mainz Biomed (NASDAQ:MYNZ) announced its earnings results on Tuesday, April, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter. The firm had revenue of $0.22 million for the quarter. Mainz Biomed had a negative trailing twelve-month return on equity of 488.05% and a negative net margin of 2,934.82%. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MYNZ) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
